Intrastromal corneal ring implant safe

Article

Intrastromal corneal ring segment (ICRS) implantation is safe and offers good visual and refractive outcomes in patients with paracentral keratoconus.

Intrastromal corneal ring segment (ICRS) implantation is safe and offers good visual and refractive outcomes in patients with paracentral keratoconus.

Dr Jose F. Alfonso and his team, based in Fernández-Vega Ophthalmological Institute, Oviedo, Spain, evaluated 56 eyes of 49 patients. The cohort study measured Snellen uncorrected and corrected distance visual acuities (UDVA and CDVA), along with residual refractive errors before implantation and six months after implantation. The ICRS was implanted into tunnels created by femtosecond laser.

Mean preoperative UDVA was 0.17 ± 0.14 and 0.41 ± 0.28 six months postoperatively. Mean CDVA was 0.70 ± 0.18 and 0.80 ± 0.17 pre and postoperatively, respectively.

Of the patients assessed, five eyes lost one lines of CDVA, 17 eyes had the same CDVA at baseline, 15 eyes gained one line, nine eyes gained two lines, seven eyes gained three lines and three eyes gained four lines.

ICRS implantation is a predictable and safe procedure for refractive correction in paracentral keratoconus cases.

The abstract can be found in the Journal of Cataract and Refractive Surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.